[EXAS] Exact Sciences Corporation


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Commercial Physical & Biological Resarch

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 14.17 Change: 0.79 (5.9%)
Ext. hours: Change: 0 (0%)

chart EXAS

Refresh chart

Strongest Trends Summary For EXAS

EXAS is in the medium-term up 30% above S&P in 6 months. In the long-term up 88% above S&P in 1 year and up 1123% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company?s stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cance

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-42.95% ROE-46.37% ROI-45.3%
Current Ratio17.69 Quick Ratio Long Term Debt/Equity0.01 Debt Ratio0.06
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities290 K Cash From Investing Activities16.76 M Cash From Operating Activities-34.5 M Gross Profit3.02 M
Net Profit-39.07 M Operating Profit-39.37 M Total Assets253.02 M Total Current Assets223.26 M
Total Current Liabilities18.73 M Total Debt4.83 M Total Liabilities28.18 M Total Revenue8.12 M
Technical Data
High 52 week92.04 Low 52 week37.84 Last close91.76 Last change-0.3%
RSI55.98 Average true range3.8 Beta0.77 Volume1.89 M
Simple moving average 20 days4.46% Simple moving average 50 days19.12% Simple moving average 200 days34.27%
Performance Data
Performance Week3.63% Performance Month16.48% Performance Quart41.76% Performance Half40.48%
Performance Year103.96% Performance Year-to-date45.42% Volatility daily2.83% Volatility weekly6.33%
Volatility monthly12.97% Volatility yearly44.92% Relative Volume250.33% Average Volume1.7 M
New High New Low


2019-04-16 14:34:40 | Did Hedge Funds Drop The Ball On EXACT Sciences Corporation EXAS ?

2019-04-12 11:26:01 | Goldman Adds EXACT Sciences To Americas Conviction List

2019-04-12 08:55:40 | Announcing: Exact Sciences NASDAQ:EXAS Stock Rocketed An Astounding 1173% In The Last Three Years

2019-04-09 10:48:47 | See what the IHS Markit Score report has to say about Exact Sciences Corp.

2019-04-08 06:00:00 | Exact Sciences schedules first-quarter 2019 earnings call

2019-04-04 16:24:49 | Exact Sciences CEO on turning company around, stock soared 140% over the past year

2019-04-01 05:00:00 | Stocks That Would Have Made You Rich Today

2019-03-27 15:30:00 | Why Exact Sciences Stock Sank Today

2019-03-27 13:13:26 | 8 Genomic Testing Stocks That Can Ease the Sting of Theranos

2019-03-26 08:26:31 | See what the IHS Markit Score report has to say about Exact Sciences Corp.

2019-03-25 07:14:11 | Should You Invest in the Invesco DWA Healthcare Momentum ETF PTH?

2019-03-21 08:19:12 | Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus

2019-03-20 15:25:07 | NASH, Allergies and Beauty Stocks: Invest or Not?

2019-03-19 10:27:42 | Exact Sciences appoints former Kansas governor, HHS secretary Sebelius to its board of directors

2019-03-19 08:00:00 | Kathleen Sebelius Appointed to Exact Sciences Board

2019-03-17 11:33:00 | Better Buy: Exact Sciences vs. Illumina

2019-03-12 15:22:25 | 5 Active Mutual Funds Worth Their Expenses

2019-03-12 07:16:00 | Why Guardant Health Is the Best Healthcare Stock You've Never Heard Of

2019-03-10 08:12:00 | The 10 Top Stocks of the 10-Year Bull Market

2019-03-08 13:35:00 | Exact Sciences Looks Vulnerable: Protect Longs

2019-03-06 00:14:00 | Exact Sciences Announces Upsizing and Pricing of 0.3750% Convertible Senior Notes Due 2027

2019-03-05 16:01:00 | Exact Sciences Announces Offering of $600 Million Convertible Senior Notes Due 2027

2019-03-04 07:00:00 | Market Trends Toward New Normal in Eaton Corporation, Kite Realty Group Trust, Intercontinental Exchange, SS&C Technologies, Exact Sciences, and Oshkosh — Emerging Consolidated Expectations, Analyst Ratings

2019-03-01 06:00:00 | Exact Sciences to participate in March investor conferences

2019-02-28 08:24:48 | The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

2019-02-27 06:00:00 | Cologuard Helps Screen Two Million People for Colorectal Cancer

2019-02-26 12:14:39 | Exact Sciences A 'Must-Own' Growth Stock, Goldman Sachs Says In Upgrade

2019-02-26 07:32:40 | What Investors Should Know About Exact Sciences Corporation’s NASDAQ:EXAS Financial Strength

2019-02-24 09:00:00 | Exact Sciences Hit a Home Run in Q4. Here's Why Sales Could Soon Soar Even More.

2019-02-22 15:42:05 | Edited Transcript of EXAS earnings conference call or presentation 21-Feb-19 10:00pm GMT

2019-02-22 00:49:18 | EXACT Sciences Corporation EXAS Q4 2018 Earnings Conference Call Transcript

2019-02-21 18:45:11 | Exact Sciences EXAS Reports Q4 Loss, Misses Revenue Estimates

2019-02-21 17:56:35 | Exact Sciences: 4Q Earnings Snapshot

2019-02-21 17:34:28 | Exact Sciences completes 934,000 Cologuard tests in 2018; annual revenue up 71%

2019-02-21 16:05:00 | Total 2018 revenue increased 71 percent to $454 million, and 934,000 people were screened with Cologuard

2019-02-21 09:28:02 | Options Traders Expect Huge Moves in Exact Sciences EXAS Stock

2019-02-20 16:06:00 | Cutera Appoints Katherine Zanotti and Joseph Whitters to its Board of Directors

2019-02-19 18:18:11 | This Week's Hottest Earnings Charts

2019-02-17 09:18:00 | Could Exact Sciences Be a Millionaire-Maker Stock?

2019-02-14 10:31:03 | Analysts Estimate Exact Sciences EXAS to Report a Decline in Earnings: What to Look Out for

2019-02-13 07:24:12 | Should You Invest in the Invesco DWA Healthcare Momentum ETF PTH?

2019-02-10 09:00:00 | The $100 Billion Investing Opportunity That Could Revolutionize Cancer Treatment

2019-02-08 08:06:46 | See what the IHS Markit Score report has to say about Exact Sciences Corp.

2019-02-07 08:07:00 | See what the IHS Markit Score report has to say about Exact Sciences Corp.

2019-02-05 08:06:46 | See what the IHS Markit Score report has to say about Exact Sciences Corp.

2019-02-04 21:47:00 | Here's Why Exact Sciences Soared 42.8% in January

2019-02-04 08:06:40 | See what the IHS Markit Score report has to say about Exact Sciences Corp.

2019-02-04 06:00:00 | Exact Sciences schedules fourth-quarter, full-year 2018 earnings call

2019-01-30 08:05:58 | See what the IHS Markit Score report has to say about Exact Sciences Corp.

2019-01-29 09:03:00 | 4 Things Exact Sciences Investors Should Know About 23andMe's New Cancer Test